ifn-kappa
Recombinant proteinexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2010 (NCT01058343)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Interferon alphaSupplementation
Interferon alpha supplementation
- Interferon alpha-17 (IFNA17) ↗
- Interferon alpha-4 (IFNA4) ↗
- Interferon alpha-14 (IFNA14) ↗
- Interferon alpha-6 (IFNA6) ↗
- Interferon alpha-8 (IFNA8) ↗
- Interferon alpha-5 (IFNA5) ↗
- Interferon alpha-10 (IFNA10) ↗
- Interferon alpha-2 (IFNA2) ↗
- Interferon alpha-1/13 (IFNA1; IFNA13) ↗
- Interferon alpha-7 (IFNA7) ↗
- Interferon alpha-21 (IFNA21) ↗
- Interferon alpha-16 (IFNA16) ↗
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- ifn-kappa
- interferon kappa
- interferon kappa
- interferon-kappa
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01058343 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2010 | Neovacs, Université catholique de Louvain |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Neovacs | For profit | 1 | 1 | 1 | 2010 |
| Université catholique de Louvain | Academic/Hospital | 1 | 0 | 1 | 2010 |
2 organizations
Page 1 / 1